

Celecoxib Inhibits Prostate Cancer Growth: Evidence of a Cyclooxygenase-2-Independent Mechanism

Manish I. Patel,^{1,2,5} Kotha Subbaramaiah,¹
Baoheng Du,¹ Mindy Chang,¹ Peiyang Yang,⁶
Robert A. Newman,⁶ Carlos Cordon-Cardo,^{2,4}
Howard T. Thaler,³ and Andrew J. Dannenberg¹

¹Department of Medicine, Weill Medical College of Cornell University; Departments of ²Urology, ³Epidemiology and Biostatistics, and ⁴Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York; ⁵Department of Surgery, University of Sydney, Sydney, Australia; and ⁶Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, Texas

ABSTRACT

Purpose: Selective cyclooxygenase-2 (COX-2) inhibitors may suppress carcinogenesis by both COX-2-dependent and COX-2-independent mechanisms. The primary purpose of this study was to evaluate whether celecoxib or rofecoxib, two widely used selective COX-2 inhibitors, possess COX-2-independent antitumor activity.

Experimental Design: PC3 and LNCaP human prostate cancer cell lines were used to investigate the growth inhibitory effects of selective COX-2 inhibitors *in vitro*. To complement these studies, we evaluated the effect of celecoxib on the growth of PC3 xenografts.

Results: COX-1 but not COX-2 was detected in PC3 and LNCaP cells. Clinically achievable concentrations (2.5–5.0 $\mu\text{mol/L}$) of celecoxib inhibited the growth of both cell lines *in vitro*, whereas rofecoxib had no effect over the same concentration range. Celecoxib inhibited cell growth by inducing a G₁ cell cycle block and reducing DNA synthesis. Treatment with celecoxib also led to dose-dependent inhibition of PC3 xenograft growth without causing a reduction in intratumor prostaglandin E₂. Inhibition of tumor growth occurred at concentrations (2.37–5.70 $\mu\text{mol/L}$) of celecoxib in plasma that were comparable with the concentrations required to inhibit cell growth *in vitro*. The highest dose of celecoxib led to a 52% reduction in tumor volume and an ~50% decrease in both cell proliferation and microvessel density. Treatment

with celecoxib caused a marked decrease in amounts of cyclin D1 both *in vitro* and *in vivo*.

Conclusions: Two clinically available selective COX-2 inhibitors possess different COX-2-independent anticancer properties. The anticancer activity of celecoxib may reflect COX-2-independent in addition to COX-2-dependent effects.

INTRODUCTION

There are two isoforms of cyclooxygenase (COX), designated COX-1 and COX-2. These enzymes catalyze the first step in the synthesis of prostaglandins (PG) from arachidonic acid. COX-1 is expressed constitutively in most tissues and seems to be responsible for the synthesis of PGs that control normal physiologic functions (1). In contrast, COX-2 is not detected in most normal tissues. However, it is induced by a variety of mitogenic and inflammatory stimuli (2–7), which results in enhanced synthesis of PGs in neoplastic and inflamed tissues (8–10).

Multiple lines of evidence suggest that COX-2 is a promising target for the prevention and treatment of cancer. COX-2 is commonly overexpressed in premalignant and malignant tissues (11–17). The most specific data supporting a cause-and-effect relationship between COX-2 and carcinogenesis come from genetic studies. Multiparous female transgenic mice that were engineered to overexpress human COX-2 in mammary glands developed mammary gland hyperplasia, dysplasia, and metastatic tumors (18). In a related study, transgenic mice that overexpress COX-2 in skin developed epidermal hyperplasia and dysplasia (19). Consistent with these findings, knocking out COX-2 reduced the incidence of skin papillomas and intestinal tumors (20, 21). In addition to the genetic evidence implicating COX-2 in carcinogenesis, numerous pharmacologic studies suggest that COX-2 is a therapeutic target. Selective inhibitors of COX-2 reduce the formation, growth, and metastases of experimental tumors (22–29), and decrease the number of intestinal tumors in familial adenomatous polyposis patients (30). It should be stressed, however, that the antitumor effects of selective COX-2 inhibitors might reflect mechanisms in addition to inhibition of COX-2 (31–37). Hence, both COX-2-dependent and COX-2-independent mechanisms may contribute to the antitumor activity of selective COX-2 inhibitors.

Numerous investigators have evaluated the expression of COX-2 in human prostate cancer with conflicting results. Several studies have suggested that COX-2 is commonly overexpressed in prostate cancer (38–41). In contrast, others have found that levels of COX-2 are extremely low or absent in the majority of prostate cancers (42, 43). Importantly, even if COX-2 overexpression proves to be uncommon in prostate cancer, selective COX-2 inhibitors could still be active agents if the COX-2-independent effects are clinically important.

Received 9/13/04; revised 10/25/04; accepted 10/26/04.

Grant support: Specialized Programs of Research Excellence grant from the National Cancer Institute, Leon Lowenstein Foundation (M. Patel and C. Cordon-Cardo), National Cancer Institute grant PO1 CA91844 (R. Newman), and Center for Cancer Prevention Research. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Andrew J. Dannenberg, New York Presbyterian-Cornell, 525 East 68th Street, Room F-206, New York, NY 10021. Phone: 212-746-4403; Fax: 212-746-4885; E-mail: ajdannenberg@med.cornell.edu.

©2005 American Association for Cancer Research.

The main purpose of the present study was to investigate whether selective COX-2 inhibitors exhibit COX-2-independent antitumor properties. Androgen-insensitive (PC3) and androgen-responsive (LNCaP) human prostate cancer cell lines were evaluated because neither cell line expressed COX-2. Clinically achievable concentrations (2.5-5.0 $\mu\text{mol/L}$) of celecoxib, a selective COX-2 inhibitor, suppressed the growth of both cell lines (44, 45). In contrast, treatment with rofecoxib, a more potent selective COX-2 inhibitor, had no effect on cell growth over the same concentration range. Notably, celecoxib also caused dose-dependent inhibition of PC3 xenograft growth. In both *in vitro* and *in vivo* studies, celecoxib suppressed cyclin D1 levels. Taken together, these findings strongly suggest that celecoxib possesses significant COX-2-independent antitumor properties and could be active even in malignancies that do not express significant amounts of COX-2 in tumor cells.

MATERIALS AND METHODS

Materials. PC3 and LNCaP cell lines were from American Type Culture Collection (Rockville, MD). RPMI 1640 and fetal bovine serum were from Invitrogen (Green Island, NY). Celecoxib and rofecoxib were from LKT Laboratories, Inc. (St. Paul, MN). Enzyme immunoassay reagents for PGE₂ assays were from Cayman Co. (Ann Arbor, MI). Nitrocellulose membranes were from Schleicher & Schuell (Keene, NH). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (thiazolyl blue), DNase-free RNase A, butylated hydroxytoluene, EDTA, and lactate dehydrogenase diagnostic kits were from Sigma Chemical Co. (St. Louis, MO). Vector stain was from Vector Laboratories (Burlingame, CA). Antibodies to COX-1, COX-2, β -actin, and cyclin D1 were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-mouse CD34 antiserum was from PharMingen (La Jolla, CA). Anti-human Ki-67 (MIB-1) was obtained from Immunotech (Marseilles, France). Enhanced chemiluminescence Western blotting detection reagents were from Perkin-Elmer Life Sciences, Inc. (Boston, MA). Male immunodeficient *nu/nu* mice were from Charles River Laboratories, Inc. (Wilmington, MA). Matrigel was from BD Biosciences (San Diego, CA). PGE₂ and PGE₂-d₄ were purchased from Cayman Chemical.

Cell Culture. PC3 and LNCaP prostate cancer cell lines were cultured in RPMI 1640 supplemented with 10% fetal bovine serum, 100 IU/mL penicillin, and 100 $\mu\text{g/mL}$ streptomycin at 37°C in a humidified 5% CO₂ incubator. All treatments with celecoxib, rofecoxib, or vehicle (0.1% Me₂SO/DMSO) were done in the presence of 10% fetal bovine serum. Cellular cytotoxicity was assessed by measurements of lactate dehydrogenase release and trypan blue exclusion. There was no evidence of toxicity in any of our experiments.

Western Blotting. Cell lysates were prepared by treating cells with lysis buffer (Cell Signaling Technology, Inc., Beverly, MA) supplemented with 1 mmol/L phenylmethylsulfonyl fluoride, 10 $\mu\text{g/mL}$ aprotinin, 10 $\mu\text{g/mL}$ trypsin inhibitor, and 10 $\mu\text{g/mL}$ leupeptin. Lysates were sonicated for 20 seconds on ice and centrifuged at 10,000 $\times g$ for 10 minutes to sediment particulate material. The protein concentration of the supernatant was measured by the method of Lowry et al. (46). SDS-PAGE was done under reducing conditions on 10% polyacrylamide

gels as described by Laemmli (47). The resolved proteins were transferred onto nitrocellulose sheets as detailed by Towbin et al. (48). The nitrocellulose membrane was then incubated with primary antibodies. Secondary antibody to IgG conjugated to horseradish peroxidase was used. The blots were probed with enhanced chemiluminescence Western blot detection system according to the manufacturer's instructions.

Prostaglandin E₂ Production in Cell Culture. One thousand cells per well were plated in 96-well dishes and allowed to attach before treatment. Amounts of PGE₂ released by cells were measured by enzyme immunoassay according to the manufacturer's instructions. Production of PGE₂ was normalized to cellular protein concentrations.

Cell Growth. PC3 cells (1×10^3 cells/well) and LNCaP cells (2×10^3 cells/well) were plated in 96-well plates. Cells were allowed to adhere and then treated with vehicle or selective COX-2 inhibitor. After treatment, the culture medium was removed and replaced with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (0.5 mg/mL). The reaction was stopped 4 hours later by removing medium and the formazan salt was allowed to dry. It was solubilized by adding 100 μL Me₂SO and the absorbance measured at 560 nm in a 96-well plate reader.

Flow Cytometry for Cell Cycle Analysis. PC3 cells were treated with vehicle or 5.0 $\mu\text{mol/L}$ celecoxib for 48 hours. Subsequently, the medium was replaced with fresh medium containing vehicle or celecoxib. After a total of 96 hours of treatment, the cells were released by treatment with trypsin-EDTA, washed and suspended in serum-free medium, counted, and then fixed overnight in 50% ethanol at 4°C. The cells (10^6 cells/mL) were then washed and resuspended in PBS (pH 7.4), 0.1% Triton X-100, 0.05 mg/mL DNase-free RNase A, and 50 $\mu\text{g/mL}$ propidium iodide before being maintained in the dark for 30 minutes at room temperature. The red fluorescence of single events was recorded using an argon ion laser at 488 nm excitation wavelength and 610 nm emission wavelength to measure DNA index on a flow cytometer (Coulter Epics XL flow cytometer, Hialeah, FL). The percentage of cells present in each phase of the cell cycle was determined using ModFIT software (Verity Software House, Topsham, ME).

DNA Synthesis Assay. Incorporation of [³H]thymidine was used to measure DNA synthesis. Cells were plated at 1×10^3 cells/well in a 96-well plate and allowed to adhere overnight before being treated with vehicle or celecoxib for 24 hours at 37°C. Subsequently, the medium was replaced with fresh medium containing vehicle or celecoxib supplemented with [³H]thymidine (0.1 $\mu\text{Ci/well}$) for 6 hours. Cells were then washed thrice with PBS. Radioactivity was then measured with a Beckman LS6800 liquid scintillation counter (Beckman, Fullerton, CA).

PC3 Xenografts. PC3 cells (1×10^6) suspended in 50% Matrigel were implanted s.c. in the flanks of 8-week-old athymic male nude mice. Six days after tumor cell inoculation, small tumors were identified. The mice were randomly distributed to each of four groups ($n = 12$ mice/group): control diet (AIN-76A; Research Diets, Inc., New Brunswick, NJ) or control diet supplemented with three different doses of celecoxib (150, 450, and 750 ppm). Mice were treated with these different diets

for the remainder of the experiment. Tumor growth was assessed twice a week by caliper measurement of tumor diameter in the longest dimension (L) and at right angles to that axis (W). Tumor volume was estimated by the formula $L \times W \times W \times \pi/6$. At the time of sacrifice, plasma was prepared from blood collected by cardiac puncture. Tumors were excised and a portion fixed in 10% buffered formalin for 24 hours for immunohistochemical studies. A second portion of tumor was snap frozen and stored at -80°C for measurements of PGE_2 and immunoblot analysis. The animal protocol was approved by the Institutional Animal Care and Use Committee of Weill Medical College of Cornell University.

Determination of Prostaglandin E_2 in Tumor Tissues.

Approximately 50 mg of frozen tissue was ground to a fine powder using a liquid-nitrogen-cooled mortar (Fisher Scientific Co., Fair Lawn, NJ). The samples were then transferred to microcentrifuge tubes and three volumes of ice-cold PBS buffer (containing 0.1% butylated hydroxytoluene and 1 mmol/L EDTA) were added before further homogenization of the sample on ice using a Knotes pellet pestle (Fisher). An aliquot (100 μL) of homogenate was transferred to a glass tube (13 \times 100 mm) and subjected to extraction of PGs using a method modified after Kempen et al. (49). Briefly, 20 μL citric acid (1 N) and 2.5 μL butylated hydroxytoluene (10%) were added to samples to prevent free radical peroxidation. Before the extraction, 10 μL deuterated PGE_2 (100 ng/mL) were added to each sample as an internal standard. PGs were then extracted with 1 mL of hexane/ethyl acetate (1:1, v/v) and vortex mixed for 2 minutes. Samples were centrifuged at $1,800 \times g$ for 10 minutes at 4°C . The upper organic layer was collected and the organic phases from three extractions were pooled and then evaporated to dryness under a stream of nitrogen at room temperature. All extraction procedures were done at minimum light levels and under cold (4°C) conditions. Samples were then reconstituted in 100 μL methanol:10 mmol/L ammonium acetate buffer (pH 8.5, 70:30, v/v) before liquid chromatography-tandem mass spectrometry analysis. The protein concentration was determined by the method of Bradford (Bio-Rad, Hercules, CA).

Liquid chromatography-tandem mass spectrometry analyses were done using a Quattro Ultima tandem mass spectrometer (Micromass, Beverly, MA) equipped with an Agilent HP 1100 binary pump high-performance liquid chromatography inlet. PGs were separated using Luna 3 μm phenyl-hexyl 2 \times 150 mm (Phenomenex, Torrance, CA). The mobile phase consisted of 10 mmol/L ammonium acetate (pH 8.5; phase A) and methanol (phase B). Flow rate was 250 $\mu\text{L}/\text{min}$ with column temperature maintained at 50°C . Sample injection volume was 25 μL . Samples were kept at 4°C during the analysis. PGE_2 was detected using electrospray negative ionization and multiple reaction (MRM) monitoring the transitions at m/z 351 to 271 for PGE_2 and m/z 355 to 275 for $\text{d}_4\text{-PGE}_2$. Fragmentation for these compounds was done using argon as the collision gas at a collision cell pressure of 2.10×10^{-3} Torr. The results were expressed as picograms of PGE_2 per milligram protein.

Determination of Celecoxib Levels in Mouse Plasma by Liquid Chromatography-Tandem Mass Spectrometry. One hundred microliters of plasma were diluted with an equal volume of 10 mmol/L ammonium acetate (pH 8.5). To this solution, 4 mL hexane/ethyl acetate (1:1, v/v) were added; the mixture was

vortex mixed for 5 minutes and then centrifuged at 4,000 rpm at 5°C for 5 minutes. The extraction was repeated twice and the upper organic layer was collected, pooled, and evaporated to dryness under a stream of nitrogen at room temperature under reduced room light conditions to limit the possibility of photooxidation. The sample was then reconstituted in 200 μL of methanol:10 mmol/L ammonium acetate (pH 8.5, 1:1, v/v). The celecoxib level in the samples was determined by liquid chromatography-tandem mass spectrometry.

Liquid chromatography-tandem mass spectrometry was operated under the same condition as described above for PGE_2 analysis with minor changes. Briefly, 10 μL of the sample was injected on a Luna 3 μm phenyl-hexyl 2 \times 150 mm analytical column (Phenomenex). Celecoxib was detected and quantified by operating the mass spectrometer in electrospray negative ion mode and monitoring the transition m/z 380.2 $>$ 316.1. Quantification was done by comparing the sample peak areas to a standard curve constructed from peak areas of extracted plasma sample added to known amounts of celecoxib.

Immunohistochemistry. Proliferation and angiogenesis were evaluated by staining for Ki-67 and CD34 as described previously (50, 51). Neutral buffered formalin-fixed tissue was embedded in paraffin. Tissue sections (5 μm) were prepared using a microtome and mounted on slides. Immunohistochemical analysis was done within 24 hours of the sections being cut. Sections were deparaffinized in xylene, rehydrated in graded alcohols, and washed in distilled water. Endogenous peroxidase activity was quenched with 0.01% H_2O_2 . Antigen retrieval was done by microwaving the sections in 10 mmol/L citric acid (pH 6.0) for 30 minutes. In addition, sections for Ki-67 analysis were treated with 0.05% trypsin, 0.05% CaCl_2 in Tris-HCl (pH 7.6) for 5 minutes at 37°C before microwave treatment. The slides were washed thrice in PBS and blocked for 30 minutes with 10% normal rabbit serum (CD34) or 10% normal horse serum (Ki-67). Tissue sections were then incubated with antiserum to mouse CD34 at 25 $\mu\text{g}/\text{mL}$ and antiserum to Ki-67 at a 1:5,000 dilution (2% bovine serum albumin in PBS) and incubated overnight at 4°C . After being washed thrice with PBS, the sections were incubated with biotinylated anti-mouse immunoglobulins at 1:100 (CD34) or 1:500 (Ki-67; Vector Laboratories) dilution for 30 minutes at room temperature. The slides were then washed thrice in PBS and labeled using 1:25 avidin-biotin peroxidase complexes (Vector Stain) for 30 minutes at room temperature. The reaction was visualized using 3,3'-diaminobenzidine. Subsequently, the slides were rinsed in tap water and counterstained with hematoxylin. The slides were then dehydrated with ethanol, rinsed with xylene, and mounted.

Proliferation was assessed by counting the number of Ki-67 positively staining nuclei and total number of cancer cells at $\times 400$ magnification, in three representative regions of the tumor. Results are expressed as the proportion of positively staining cells over the total number of cells. Microvessel density was assessed by counting the number of microvessels at $\times 200$ magnification in three fields that had the highest vascularization. The results are expressed as an average number of microvessels per field.

Statistics. Xenograft tumor growth was compared between dosage groups by fitting a quadratic curve to the log tumor volume from days 9 to 30 for each mouse. The linear and

quadratic coefficients were then compared jointly using repeated measures ANOVA to test overall dose effect and pair-wise contrasts between successive doses. Results are expressed descriptively as the mean \pm SE. All other comparisons between groups were made by the two-tailed Student's *t* test with results presented as the mean \pm SD. A difference between groups of $P < 0.05$ was considered significant.

RESULTS

COX-2 Is Not Expressed in Human Prostate Cancer Cell Lines. Levels of COX enzymes and PGE₂ biosynthesis were evaluated in androgen-independent PC3 and androgen-dependent LNCaP prostate cancer cell lines. COX-2 was not detected by immunoblot (Fig. 1A) or Northern blot (data not shown) analysis in either cell line. In contrast, COX-1 was detected in both cell lines (Fig. 1B). We also used a pharmacologic approach to confirm the absence of COX-2 in these cell lines. Extremely low levels of basal production of PGE₂ were detected in both PC3 and LNCaP cells (Fig. 1C). Consistent with the absence of COX-2 expression, neither treatment with 5.0 μ mol/L celecoxib (Fig. 1C) nor 5.0 μ mol/L NS398 (data not shown), another selective COX-2 inhibitor, suppressed PGE₂ biosynthesis in PC3 or LNCaP cells.

Celecoxib Inhibited Prostate Cancer Cell Growth. As detailed above, it has been suggested that the anticancer properties of selective COX-2 inhibitors may be due, in part, to COX-2-independent effects. It was important, therefore, to investigate whether celecoxib or rofecoxib modulated the growth of either PC3 or LNCaP cells. As shown in Fig. 2A, treatment with celecoxib caused dose-dependent inhibition of PC3 cell growth. Treatment with 2.5 and 5.0 μ mol/L celecoxib for 4 days inhibited cell growth by 17% and 37%, respectively (Fig. 2A). In contrast, rofecoxib, a selective COX-2 inhibitor that is more potent than celecoxib, did not suppress the growth of PC3 cells until concentrations of 10.0 μ mol/L or more were used (Fig. 2A). To prove that these effects were not unique to PC3 cells, we also compared the effects of celecoxib and rofecoxib on the growth of LNCaP cells. Consistent with the findings in PC3 cells, celecoxib caused dose-dependent inhibition of LNCaP cell growth whereas rofecoxib had no effect even at concentrations as high as 10.0 μ mol/L (Fig. 2B).

Flow cytometry was done to further define the mechanism by which celecoxib inhibited the growth of PC3 cells. Treatment with 5.0 μ mol/L celecoxib led to an increase in the percentage of cells in G₀-G₁ (62-80%) and a corresponding decrease in the percentage of cells in S phase (23-9%; Fig. 3A). Celecoxib also caused a dose-dependent reduction in [³H] thymidine incorporation (Fig. 3B).

Changes in amounts of cyclin D1 can alter progression to S phase. To begin to elucidate the mechanism by which celecoxib caused a G₀-G₁ arrest, levels of cyclin D1 were measured. Treatment with 5.0 μ mol/L celecoxib led to a profound decrease in the amounts of cyclin D1 (Fig. 4).

Celecoxib Inhibited PC3 Xenograft Growth. Based on the *in vitro* findings described above, it was important to investigate whether celecoxib had comparable growth inhibitory effects *in vivo*. The PC3 xenograft model was used to assess whether celecoxib inhibited tumor growth. Treatment with

vehicle or celecoxib (150, 450, and 750 ppm) was initiated once small tumors had formed (Fig. 5). Celecoxib caused dose-dependent inhibition of tumor growth. At sacrifice, tumor volumes were reduced by 26%, 41%, and 52% in mice treated with 150, 450, and 750 ppm celecoxib, respectively. Notably, at the time of sacrifice, levels of celecoxib in plasma ranged from 2.37 μ mol/L in the group treated with 150 ppm celecoxib to 5.7 μ mol/L in the group that received 750 ppm celecoxib (Fig. 5). These plasma levels of celecoxib are comparable with the concentrations used to suppress PC3 cell growth *in vitro* (Fig. 2). We also investigated whether treatment with celecoxib




Fig. 1 COX-2 is not expressed in PC3 or LNCaP prostate cancer cell lines. Cellular lysate protein from PC3 and LNCaP cells (100 μ g/lane) was loaded onto a 10% SDS-polyacrylamide gel, electrophoresed, and subsequently transferred onto nitrocellulose. Immunoblots were probed with antibodies to COX-2 (A), COX-1 (B), and β -actin, respectively. C, PC3 and LNCaP cells were grown in culture medium treated with vehicle (-) or 5 μ mol/L celecoxib (+) for 48 hours. Production of PGE₂ was determined by enzyme immunoassay. Columns, means; bars, SD; $n = 6$.




Fig. 2 Effect of selective COX-2 inhibitors on the growth of PC3 and LNCaP prostate cancer cells. PC3 (A) and LNCaP (B) cells were treated with 0 to 10.0 μmol/L celecoxib or rofecoxib. At the end of 48 hours, culture medium was replaced with fresh medium containing vehicle or the indicated concentration of drug. After a total of 96 hours of treatment, cell number was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and expressed relative to vehicle-treated cells. Columns, means; bars, SD ($n = 6$; *, $P < 0.05$, **, $P < 0.01$).

suppressed intratumor PGE₂ levels. A small statistically insignificant decrease in amounts of PGE₂ was detected in tumors from mice in each of the groups treated with celecoxib (Fig. 5). Thus, whereas celecoxib caused dose-dependent inhibition of tumor growth, levels of PGE₂ were essentially identical in tumor tissues from the different treatment groups.

Treatment with Celecoxib Inhibited Angiogenesis and Cell Proliferation in PC3 Xenografts. The inhibition of tumor growth by celecoxib could reflect reduced cell proliferation

or increased apoptosis. Examination of H&E-stained tumor sections from mice that received control or celecoxib supplemented diets revealed very few apoptotic bodies in either group and further evaluation of apoptosis was not pursued (data not shown). Nuclear staining of Ki-67 was used to assess cell proliferation. Treatment with celecoxib caused nearly a 50% decrease in cell proliferation ($P < 0.001$; Fig. 6A, B, and E). Because inhibition of angiogenesis can contribute to reduced cell proliferation, we also determined the effects of celecoxib on microvessel density. Angiogenesis was evaluated by staining for CD34, an antigen present in endothelial cells. Microvessel




Fig. 3 Celecoxib caused G₀-G₁ cell cycle arrest and inhibited DNA synthesis in PC3 cells. A, representative DNA histogram of cells after treatment with vehicle (control) or 5.0 μmol/L celecoxib for 96 hours. Celecoxib caused an increase in the percentage of cells in G₀-G₁ and a corresponding decrease in the percentage of cells in S phase. The indicated percentages represent a mean of three independent experiments. B, effect of celecoxib on DNA synthesis. PC3 cells were treated with 0 to 5.0 μmol/L celecoxib for 24 hours. [³H]thymidine was then added for 6 hours and DNA synthesis quantified. [³H]thymidine incorporation was expressed relative to vehicle-treated cells. Columns, means; bars, SD ($n = 6$, *, $P < 0.05$; **, $P < 0.01$).




Fig. 4 Celecoxib inhibits cyclin D1 expression in PC3 cells. PC3 cells were treated with vehicle (C) or 5.0 $\mu\text{mol/L}$ celecoxib (T) for 24 or 96 hours. Cellular lysate protein (100 $\mu\text{g/lane}$) was loaded onto a 10% SDS-polyacrylamide gel, electrophoresed, and subsequently transferred onto nitrocellulose. The immunoblot was probed with antibodies to cyclin D1 and β -actin, respectively. Reduced levels of cyclin D1 were detected following 96 hours of treatment with celecoxib.

density decreased by almost 50% in tumors from mice treated with celecoxib ($P = 0.02$; Fig. 6C, D, and E). Reduced cell proliferation occurred in regions of the tumor in which significant reductions in angiogenesis were detected, suggesting that decreased cell proliferation may be a consequence of reduced angiogenesis. In an attempt to define the mechanism underlying celecoxib-mediated inhibition of tumor cell proliferation in xenografts, immunoblot analysis was done. As shown in Fig. 7, treatment with celecoxib led to a profound decrease in amounts of cyclin D1. These findings are similar to the results in PC3 cells treated with celecoxib *in vitro* (Fig. 4).

DISCUSSION

Several investigators have suggested that selective COX-2 inhibitors possess anticancer activity because of both COX-2-dependent and COX-2-independent effects (11, 31–37). This raises the intriguing possibility that selective COX-2 inhibitors may be active agents even when COX-2 is not detected in a

target tissue. Two studies found that COX-2 was expressed in prostate cancer much less frequently than in many other epithelial malignancies (42, 43). With this in mind, we elected to focus on prostate cancer to determine whether selective COX-2 inhibitors possess important COX-2-independent anti-tumor properties.

Initially, we found that COX-2 was not expressed in either PC3 or LNCaP cells. This conclusion was based on the results of immunoblotting, Northern blot analysis, and the inability to suppress PGE_2 biosynthesis with two different selective COX-2 inhibitors. Although the absence of COX-2 in these cell lines agrees with some reports (42, 52), other investigators have detected COX-2 in PC3 cells (34, 53). This apparent difference is likely to reflect the use of different clones by different laboratories. It is noteworthy that clinically achievable concentrations of celecoxib (44, 45) suppressed the growth of both PC3 and LNCaP cell lines whereas rofecoxib had no effect over the same concentration range. Because COX-2 is not expressed in these two cell lines, the growth inhibitory effect of celecoxib must reflect a COX-2-independent mechanism. Although other studies have suggested that selective COX-2 inhibitors including celecoxib possess COX-2-independent activity (31–37), the significance of this work has been questioned because extremely high concentrations of drug were used (31, 54, 55). To our knowledge, this is the first study to show that a selective COX-2 inhibitor has COX-2-independent antitumor properties using a concentration of drug that is clinically achievable (44, 45).

To further investigate the mechanism underlying the growth inhibitory effects of celecoxib, flow cytometry was done. Celecoxib caused an accumulation of cells in G_0 - G_1 and





Fig. 5 Celecoxib causes dose-dependent inhibition of PC3 xenograft growth. PC3 cells were inoculated into the flanks of nude mice. Six days after tumor cell inoculation, mice were randomized to control diet (vehicle) or control diet supplemented with 150, 450, or 750 ppm celecoxib (12 mice/group). Tumor volume was assessed at multiple time points for all mice. At the time of sacrifice, plasma was obtained and levels of celecoxib determined. Intratumoral amounts of PGE_2 were also measured. Points, means; bars, SE. Statistically significant inhibition of tumor growth was achieved at all celecoxib doses compared with vehicle fed mice (^a $P < 0.05$, ^b $P < 0.01$). Treatment with 750 ppm led to greater inhibition of tumor growth than treatment with either 150 ppm (^c $P < 0.01$) or 450 ppm (^d $P < 0.05$) celecoxib. Treatment with celecoxib did not cause a statistically significant decrease in levels of intratumoral PGE_2 .



E

	Proliferative Index	Microvessel Density
Control	71.2±8.8%	10.5±3.2
Treated (750ppm celecoxib)	38.7±10.6%*	5.7±2.6**

Fig. 6 Celecoxib inhibits cell proliferation and angiogenesis in PC3 xenografts. PC3 cells were inoculated into the flanks of nude mice. Six days after tumor cell inoculation, mice were randomized to control diet (vehicle) or control diet supplemented with 750 ppm celecoxib. After 25 days of treatment with control or celecoxib-containing diet, mice were sacrificed. Tumor tissue was formalin fixed and paraffin embedded. Immunohistochemistry was done to assess cell proliferation (Ki-67) and vascular density (CD34). Representative tumor sections stained for Ki-67 are shown ($\times 400$) from mice fed control diet (A) or 750 ppm celecoxib (B). Representative tumor sections stained for CD34 are shown ($\times 400$) from mice fed control diet (C) or 750 ppm celecoxib (D). E, summary of the findings for proliferative index and microvessel density in tumors from mice fed control diet versus control diet supplemented with 750 ppm celecoxib. Data are means \pm SD ($n = 6$ per group; *, $P < 0.001$ and **, $P < 0.02$).

a corresponding decrease in S phase. Similar effects of celecoxib have been observed in rat prostate cancer cells (56). Consistent with these results, a dose-dependent decrease in [3 H]thymidine incorporation was observed in our study. Changes in cyclin D1 expression impact on the progression of cells from G₁ to S. Hence, the discovery that treatment with celecoxib caused a significant reduction in amounts of cyclin D1 is significant.

We next used an experimental model of prostate cancer to attempt to translate these *in vitro* findings. Treatment with celecoxib caused a dose-dependent decrease in the growth of PC3 xenografts. To better understand the growth inhibitory effects of celecoxib, measurements of microvessel density and cell proliferation were done. Treatment with celecoxib caused nearly a 50% decrease in both microvessel density and cell proliferation. These findings are consistent with prior evidence that selective COX-2 inhibitors can suppress the growth of transplantable tumors by inhibiting angiogenesis and cell proliferation (26, 28, 57–60). Although celecoxib inhibited the growth of cultured PC3 cells by a COX-2-independent mechanism, we acknowledge that our *in vivo* findings do not allow us to exclude a COX-2-dependent growth inhibitory

effect. Because COX-2 is expressed in neovasculature (58), celecoxib may have inhibited tumor growth at least, in part, by a COX-2-dependent antiangiogenic mechanism. Because the vasculature comprises a relatively small proportion of the xenograft, celecoxib may have suppressed tumor growth by inhibiting angiogenesis without causing a decrease in intra-tumor PGE₂. Based on our *in vitro* findings, levels of cyclin D1 were measured in tumor samples. Similar to what was observed in cultured PC3 cells, celecoxib caused a reduction in amounts of cyclin D1 in PC3 xenografts. This finding is consistent with previous evidence that a selective COX-2 inhibitor suppressed levels of cyclin D1 in an experimental model of colorectal carcinoma (29). Importantly, the suppressive effects that we observed occurred at plasma concentrations of celecoxib that were essentially identical to the doses required to induce COX-2-independent changes *in vitro*. Thus, it remains uncertain if the observed decrease in tumor cell proliferation in PC3 xenografts is a consequence of reduced angiogenesis, a COX-2-independent growth inhibitory effect of celecoxib as observed *in vitro*, or a combination of both mechanisms.

In summary, our *in vitro* studies show that clinically achievable concentrations of celecoxib inhibit the growth of prostate cancer cells by a COX-2-independent mechanism. Moreover, the discovery that celecoxib and rofecoxib have different COX-2-independent effects raises the possibility that the antitumor activity of selective COX-2 inhibitors could differ. Currently, the dose of selective COX-2 inhibitor used in chemoprevention and cancer treatment studies is based on the amount of drug required to inhibit COX-2 activity (61). Whether different doses will be required to optimize the COX-2-independent effects and therefore the antitumor activity of these drugs should be explored. We emphasize that the results of this study do not detract from the substantial body of evidence indicating that COX-2 is a rational target for anticancer therapy. Our study does suggest, however, that COX-2-independent effects may also be important for understanding the overall antitumor activity of selective COX-2 inhibitors.




Fig. 7 Celecoxib inhibits cyclin D1 expression in PC3 xenografts. PC3 cells were inoculated into the flanks of nude mice. Six days after tumor cell inoculation, mice were randomized to control diet (vehicle) or control diet supplemented with 750 ppm celecoxib. After 25 days of treatment with control or celecoxib-containing diet, mice were sacrificed and tumor tissue procured. Tumor cell lysate protein (100 μ g/lane) from six control mice (lanes 1–6) and six celecoxib-treated mice (lanes 7–12) was loaded onto a 10% SDS-polyacrylamide gel, electrophoresed, and subsequently transferred onto nitrocellulose. The immunoblot was probed with antibodies to cyclin D1 and β -actin, respectively. Xenografts from celecoxib-treated mice showed a marked reduction in amounts of cyclin D1.

REFERENCES

1. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. *Annu Rev Biochem* 2000;69:145–82.
2. Kujubu DA, Fletcher BS, Vamum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. *J Biol Chem* 1991;266:12866–72.
3. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. *J Biol Chem* 1993;268:9049–54.
4. DuBois RN, Awad J, Morrow J, Roberts LJ, Bishop PR. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor- α and phorbol ester. *J Clin Invest* 1994; 93:493–8.
5. Inoue H, Yokoyama C, Hara S, Tone Y, Tanabe T. Transcriptional regulation of *human prostaglandin-endoperoxide synthase-2* gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. *J Biol Chem* 1995;270:24965–71.
6. Subbaramaiah K, Telang N, Ramonetti JT, et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. *Cancer Res* 1996;56:4424–9.
7. Mestre JR, Subbaramaiah K, Sacks PG, et al. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. *Cancer Res* 1997;57:2890–5.
8. Bennett A. The production of prostanoids in human cancers, and their implications for tumor progression. *Prog Lipid Res* 1986;25: 539–42.
9. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. *J Lab Clin Med* 1993;122:518–23.
10. Sharon P, Ligumsky M, Rachmilewitz D, Zor U. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. *Gastroenterology* 1978; 75:638–40.
11. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. *Trends Pharmacol Sci* 2003;24:96–102.
12. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of *cyclooxygenase 2* gene expression in human colorectal adenomas and adenocarcinomas. *Gastroenterology* 1994;107:1183–8.
13. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. *Cancer Res* 1997;57:1276–80.
14. Parrett ML, Harris RE, Joarder FS, Ross MS, Clausen KP, Robertson FM. Cyclooxygenase-2 expression in human breast cancer. *Int J Oncol* 1997;10:503–7.
15. Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. *Cancer Res* 1999;59:991–4.
16. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. *Cancer Res* 1999;59:987–90.
17. Kulkarni S, Rader JS, Zhang F, et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. *Clin. Cancer Res* 2001; 7:429–34.
18. Liu CH, Chang SH, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. *J Biol Chem* 2001;276:18563–9.
19. Neufang G, Furstemberger G, Heidt M, Marks F, Muller-Decker K. Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin. *Proc Natl Acad Sci U S A* 2001;98:7629–34.
20. Tiano HF, Loftin CD, Akunda J, et al. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. *Cancer Res* 2002;62:3395–401.
21. Chulada PC, Thompson MB, Mahler JF, et al. Genetic disruption of PtgS-1, as well as of PtgS-2, reduces intestinal tumorigenesis in Min mice. *Cancer Res* 2000;60:4705–8.
22. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. *Cancer Res* 1998;58:409–12.
23. Fischer SM, Lo H-H, Gordon GB, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. *Mol Carcinog* 1999;25:231–40.
24. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. *Cancer Res* 2000;60:2101–3.
25. Sheng H, Shao J, Kirkland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. *J Clin Invest* 1997;99:2254–9.
26. Sawaoka H, Kawano S, Tsuji S, et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. *Am J Physiol* 1998;274:G1061–7.
27. Howe LR, Subbaramaiah K, Patel J, et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. *Cancer Res* 2002;62:5405–7.
28. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer *in vivo*. *J Urol* 2000;164:820–5.
29. Yao M, Kargman S, Lam EC, et al. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. *Cancer Res* 2003;63:586–92.
30. Steinbach G, Lynch PM, Phillips RKS, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. *N Engl J Med* 2000;342:1946–52.
31. Hwang DH, Fung V, Dannenberg AJ. National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and -independent mechanisms. *Neoplasia* 2002;4:91–7.
32. Zhang X, Morham SG, Langenbach R, Young DA. Malignant transformation and antineoplastic actions of nonsteroidal anti-inflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. *J Exp Med* 1999;190:451–60.
33. Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM, Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. *Cancer Res* 2002;62:2029–33.
34. Song X, Lin H-P, Johnson AJ, et al. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. *J Natl Cancer Inst* 2002;94:585–91.
35. Liu G, Ma WY, Bode AM, Zhang Y, Dong Z. NS-398 and piroxicam suppress UVB-induced activator protein 1 activity by mechanisms independent of cyclooxygenase-2. *J Biol Chem* 2003;278:2124–30.
36. Shureiqi I, Chen D, Lotan R, et al. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. *Cancer Res* 2000;60:6846–50.
37. Wu J, Xia HHX, Tu SP, et al. 15-Lipoxygenase-1 mediates cyclooxygenase-2 inhibitor-induced apoptosis in gastric cancer. *Carcinogenesis* 2003;24:243–7.
38. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Overexpression of cyclooxygenase-2 in human prostate adenocarcinoma. *Prostate* 2000;42:73–8.
39. Kirschenbaum A, Klausner AP, Lee R, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. *Urology* 2000;56:671–6.
40. Madaan S, Abel PD, Chaudhary KS, et al. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. *BJU Int* 2000;86:736–41.
41. Tanji N, Kikugawa T, Yokoyama M. Immunohistochemical study of cyclooxygenases in prostatic adenocarcinoma; relationship to apoptosis and Bcl-2 protein expression. *Anticancer Res* 2000;20:2313–9.

42. Zha S, Gage WR, Sauvageot J, et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. *Cancer Res* 2001;61:8617–23.
43. Shappell SB, Manning S, Boeglin WE, et al. Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. *Neoplasia* 2001;3:287–303.
44. Ferrandina G, Ranelletti FO, Legge F, et al. Celecoxib modulates the expression of cyclooxygenase-2, Ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study. *Clin Cancer Res* 2003;9:4324–31.
45. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, Fitzgerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase-2 (COX)-2: the human pharmacology of a selective inhibitor of COX-2. *Proc Natl Acad Sci U S A* 1999;96:272–7.
46. Lowry OH, Rosebrough NJ, Farr AL, Randell RJ. Protein measurement with the Folin phenol reagent. *J Biol Chem* 1951;193:265–75.
47. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature (Lond.)* 1970;227:680–5.
48. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. *Proc Natl Acad Sci U S A* 1979;76:4350–4.
49. Kempen EC, Yang P, Felix E, Madden T, Newman RA. Simultaneous quantification of arachidonic acid metabolites in cultured tumor cells using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. *Anal Biochem* 2001;297:183–90.
50. Hoos A, Nissan A, Stojadinovic A, et al. Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis. *Clin Cancer Res* 2002;8:3841–9.
51. Fox WD, Higgins B, Maiese KM, et al. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. *Clin Cancer Res* 2002;8:3226–31.
52. Hong SH, Avis I, Vos MD, Martinezy A, Treston AM, Mulshine JL. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. *Cancer Res* 1999;59:2223–8.
53. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. *J Biol Chem* 2000;275:11397–403.
54. Hawk ET, Viner JL, Dannenberg AJ, DuBois RN. COX-2 in cancer. A player that's defining the rules. *J Natl Cancer Inst* 2002;94:545–6.
55. Williams CS, Watson AJM, Sheng H, Helou R, Shao J, DuBois RN. Celecoxib prevents tumor growth *in vivo* without toxicity to normal gut: lack of correlation between *in vitro* and *in vivo* models. *Cancer Res* 2000;60:6045–51.
56. Narayanan BA, Condon MS, Bosland MC, Narayanan NK, Reddy BS. Suppression of *N*-methyl-*N*-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s). *Clin Cancer Res* 2003;9:3503–13.
57. Nishimura G, Yanoma S, Mizuno H, Kawakami K, Tsukuda MA. Selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. *Jpn J Cancer Res* 1999;90:1152–62.
58. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. *Cancer Res* 2000;60:1306–11.
59. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. *J Clin Invest* 2000;105:1589–94.
60. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells *in vivo*. *Cancer Res* 2002;62:625–31.
61. Altorki NK, Keresztes RS, Port JL, et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. *J Clin Oncol* 2003;21:2645–50.

Clinical Cancer Research

Celecoxib Inhibits Prostate Cancer Growth: Evidence of a Cyclooxygenase-2-Independent Mechanism

Manish I. Patel, Kotha Subbaramaiah, Baoheng Du, et al.

Clin Cancer Res 2005;11:1999-2007.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/11/5/1999>

Cited articles This article cites 59 articles, 35 of which you can access for free at:
<http://clincancerres.aacrjournals.org/content/11/5/1999.full#ref-list-1>

Citing articles This article has been cited by 36 HighWire-hosted articles. Access the articles at:
<http://clincancerres.aacrjournals.org/content/11/5/1999.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://clincancerres.aacrjournals.org/content/11/5/1999>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.